



SASKATCHEWAN FORMULARY BULLETIN

Update to the 62nd Edition of the Saskatchewan Formulary

<u>Product</u>	<u>DIN</u>	<u>Pre-Markup (\$)</u>
----------------	------------	------------------------

New Non-Interchangeable Full Formulary Listings Effective October 1, 2012:

Jamp-Colchicine (colchicine) (JPC)

0.6mg tablet	02373823	0.2565
1mg tablet	00373831	0.5080

MediSure (MDI)

Blood Glucose Test Strip	00951177	0.4500
--------------------------	----------	--------

New Exception Drug Status (EDS) Listings Effective October 1, 2012:

Visanne (dienogest) (BAY)

2mg tablet	02374900	1.9643
------------	----------	--------

For the management of pelvic pain associated with endometriosis in patients for whom one or more less costly hormonal options (oral contraceptives and medroxyprogesterone acetate depot injection suspensions) are either ineffective or cannot be used.

Note: An adequate trial with oral contraceptives or medroxyprogesterone acetate depot injection suspensions shall be defined as a six month interval.

Revised Exception Drug Status Criteria (see italicized portion) Effective October 1, 2012:

- **aripiprazole, tablet, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg (Abilify-BMY)**

For the treatment of schizophrenia *and schizoaffective disorders*.

- **hepatitis drugs (i.e., Hepsera, Baraclude, Intron A, Heptovir, Pegasys, Pegasys RBV, Pegetron, Pegetron Redipen, Viread, Incivek, Victrelis and Victrelis Triple)**

Note: This product should be used in consultation with a specialist in this area.

- **risedronate sodium, tablet, 5mg, 35mg, 75mg, 150mg (Actonel-PGA and generic formulations), delayed release tablet, 35mg (Actonel 35mg DR-WCI)**
and
- **alendronate sodium, tablet, 10mg, 70mg, oral solution, 70mg/75mL (Fosamax-MSD and generic formulations)**
and
- **alendronate sodium/vitamin D3 (cholecalciferol), tablet, 70mg/5600IU (Fosavance-MSD)**

For the treatment of osteoporosis with a 20% or greater 10-year fracture risk.

Note: The fracture risk can be determined by the World Health Organization's fracture risk assessment tool, FRAX, or the most recent (2010) version of the Canadian Association of Radiologist and Osteoporosis Canada (CAROC) table. The links to the tools are available at:

<http://www.shef.ac.uk/FRAX/tool.jsp?country=19>

<http://www.osteoporosis.ca/multimedia/pdf/CAROC.pdf>

The Drug Plan will not require FRAX or CAROC documentation to be included with EDS applications for oral bisphosphonates.

Drugs Reviewed and Not Approved for Listing in the Saskatchewan Formulary:

- **Gelnique, topical gel, 100mg/gm (10%) (oxybutynin chloride) (WAT)**
- **Eliquis, tablet, 2.5mg (apixaban) (BMY)**
- **Benlysta, powder for solution, 120mg/5ml vial, 400mg/20ml vial (belimumab) (GSK)**
- **Lucentis, injection solution, 10mg/ml (ranibizumab) (NVR) – for diabetic macular edema**
- **pms-Citalopram, tablet, 10mg (citalopram hydrobromide) (PMS)**

**Saskatchewan Ministry of Health
Drug Plan and Extended Benefits Branch
2nd Floor, 3475 Albert Street
Regina, Saskatchewan S4S 6X6
(306) 787-3317
1-800-667-7581**

This Bulletin is not to be reproduced or republished except with the approval of the Saskatchewan Ministry of Health. Inquiries should be directed to the address or telephone numbers shown at left.